BioCentury on BioBusiness,
Table: Cracking the combination
Back to the parent article
Monday, October 22, 2012
New Phase II data show interferon-free combinations of
HCV therapeutics being developed by Abbott Laboratories (NYSE:ABT) and Bristol-Myers
Squibb Co. (NYSE:BMY) could produce sustained virologic response (SVR)
rates >90% in patients infected with HCV genotype 1 without the use of a
nucleotide-based NS5B inhibitor.
The best data previously reported were from Gilead
Sciences Inc. (NASDAQ:GILD) and BMS, which announced Phase II results in
April showing 100% sustained virologic response (SVR) in patients
receiving the nucleotide NS5B inhibitor sofosbuvir (GS-7977) and the NS5A
inhibitor daclatasvir. Gilead declined to advance the combination into Phase
III. The biotech is instead developing sofosbuvir with its own NS5A inhibitor,
GS-5855. Preliminary results from that combination are expected to be presented
at the American Association for the Study of Liver Diseases (AASLD) meeting
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]